BioSpace News Archive

Nexus Pharmaceuticals LLC, a privately-owned U.S.-based healthcare company has announced the appointment of Edgar Lee and Mike Warmuth to the company’s board of directors, effective immediately.

23andMe Holding Co., a leading human genetics and biopharmaceutical company, announced that it will report financial results for the fiscal year 2023 fourth quarter and full year after the market closes on Thursday, May 25, 2023.

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, the European Hematology Association (EHA) Congress, and the International Conference on Malignant Lymphoma (ICML), underscoring the company’s momentum towards delivering treatment options with the hope to transform clinical outcomes for patients.

ALX Oncology Holdings Inc. reported financial results for the first quarter ended March 31, 2023 and provided clinical development and operational highlights.

Helius Medical Technologies, Inc., a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, announced results for the quarter ended March 31, 2023.

Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2023 and provided a business update.

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical leader in cell cycle checkpoint control developing innovative medicines based on cancer cell biology, announced today first quarter financial results and provided a business update.

Sientra, Inc., a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, announced its financial results for the first quarter that ended March 31, 2023.

TELA Bio, Inc. reported financial results for the first quarter ended March 31, 2023.

ClearPoint Neuro, Inc., a global therapy-enabling platform company providing navigation and delivery to the brain, announced financial results for its first quarter ended March 31, 2023.